Empagliflozin + Metformin HCI Extended-release
Diajard-MXR (Empaglifozin+Metformin extended release) is a prescription medicine used to: Diabetes Mellitus Type-2
Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. Or had any previous episode of ketoacidosis.
DOSAGE & ADMISITRATION:
Take Diajard-MXR (empagliflozin and metformin) orally once daily with a meal in the morning. Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin hydrochloride 2000mg and empagliflozin 25mg
Diabetes Type-2 patients on prescription of a doctor
It is contraindicated in patients with moderate to severe renal impairment (eGFR less than 45 mL/min/1.73 m2 ), end stage renal disease, or dialysis. Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin
The reported adverse events are; hypotension, ketoacidosis, acute kidney injury and impairment in renal function, urosepsis and pyelonephritis, hypoglycemia with concomitant use with insulin and insulin secretagogues, necrotizing fasciitis of the perineum (Fournier’s gangrene), genital mycotic infections, hypersensitivity reactions, increased low-density lipoprotein cholesterol, urinary tract infection (asymptomatic bacteriuria, cystitis), female genital mycotic infection
Diajard-MXR is presented in , 5/1000, 10/1000, 12.5/500 or 25/1000 mg
Do not store above 30°C,keep in dry place, protect from light.
Patient should consult with their physician before taking any medicine